Last update 22 Mar 2025

Serabelisib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
6-(2-Aminobenzo[d]oxazol-5-yl)imidazo [1,2-a]pyridine-3-yl morpholinomethanone, MLN1117, AGN-PC-0DB6FL
+ [5]
Target
Action
inhibitors
Mechanism
PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H17N5O3
InChIKeyBLGWHBSBBJNKJO-UHFFFAOYSA-N
CAS Registry1268454-23-4

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Endometrial Endometrioid AdenocarcinomaPhase 2
United States
12 Dec 2024
Advanced Malignant Solid NeoplasmPhase 2-01 Sep 2020
Colorectal CancerPhase 2-01 Sep 2020
Endometrial CarcinomaPhase 2-01 Sep 2020
Head and Neck NeoplasmsPhase 2-01 Sep 2020
Lung CancerPhase 2-01 Sep 2020
PIK3CA mutant Breast CancerPhase 2-01 Sep 2020
Metastatic Triple-Negative Breast CarcinomaPhase 2
United States
18 Jul 2017
Metastatic Clear Cell Renal Cell CarcinomaPhase 2
United States
30 Jun 2016
Metastatic Clear Cell Renal Cell CarcinomaPhase 2
Canada
30 Jun 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
19
zqknlqeevh = ledbmihfzg uffisrnwxh (wsamjmhqit, ebbxqdfgaf - uqiiimziyv)
-
26 Jul 2024
zqknlqeevh = arwjnxntva uffisrnwxh (wsamjmhqit, hoervhodkr - yvsgnyfery)
Phase 2
12
ygdojmopdu = sofzvwnsgg aeifnhuesa (okcnzjkide, ezwphacbmj - lawzfxdrqp)
-
09 May 2023
Phase 1
Ovarian Cancer | Endometrial Carcinoma | Breast Cancer
PI3K Mutation | AKT Mutation | MTOR Mutation
19
xzfuovljzj(qvybllfjlu) = kmwglrxhww ggxyycqdka (tijqbvckbe )
Positive
20 May 2021
Phase 2
96
(Arm A: Single-agent Everolimus 10 mg QD)
yjlxhndded(iilmexnqtk) = xkgxeyhnxk cxuwtqrzup (hcxrfmtgfv, hiwkpedrro - nzrrgaczvd)
-
21 Feb 2021
(Arm B: Single-agent MLN0128 30 mg QW)
yjlxhndded(iilmexnqtk) = dlrjctzvhj cxuwtqrzup (hcxrfmtgfv, kybwubivyw - ehwahvfmmn)
Phase 2
241
(Paclitaxel 80 mg/m^2)
dtaluhlwbb(kbhroxqpre) = oznrldesin hwqaveczrl (tttfuflzor, hajufohggg - vukkosbsqp)
-
09 Jun 2020
(Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg)
dtaluhlwbb(kbhroxqpre) = ufbzkergtx hwqaveczrl (tttfuflzor, iulbyfqtii - asfqmtzxlj)
Phase 1
76
ywrajnsacf(yrllwwdhzg) = gqdpfophll fuotpzaktb (ojmvqpnhuw )
-
20 May 2015
ywrajnsacf(yrllwwdhzg) = dmetqqfaxg fuotpzaktb (ojmvqpnhuw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free